SRR1313168
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | FCD3124F-0F41-448E-B2B9-D9934D4EC1A7 | — | — | 0.882 |
| 2 | E92DD0CC-DD0F-469D-8357-228A4A67DBD6 | — | — | 0.875 |
| 3 | A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9 | — | — | 0.871 |
| 4 | fca4c327-dfab-4455-84a8-f890a7326132 | — | — | 0.868 |
| 5 | TCGA-IQ-A61E-01A-22R-A30B-07 | — | — | 0.868 |
| 6 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.862 |
| 7 | CA6E11F4-8B85-4C73-9B48-C28F5D5D91D6 | — | — | 0.860 |
| 8 | DF145DF3-D7FD-48C9-ADC8-0B8618DC65A8 | — | — | 0.845 |
| 9 | 9E5B5D00-45A2-48A9-9F57-0B4AAE9E4E25 | — | — | 0.843 |
| 10 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.460 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.350 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.210 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |